CO-OCCURRENCE OF JAK2/CALR-POSITIVE MYELOPROLIFERATIVE DISORDER AND BCR-ABL-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA TREATED WITH COMBINATION OF TYROSINE KINASE INHIBITORS AND RUXOLITINIB.
Katia Paciaroni(ASL Roma), Tommaso Caravita di Toritto(Fondazione Gimema Onlus), Selenia Campagna(ASL Roma), Giulia Dragonetti(ASL Roma), Enrico Maffini(Istituto di Ematologia di Bologna), Francesca Celesti(Ospedale di Belcolle), Nicoletta Villivà(Azienda Sanitaria Locale Roma 3), Mariangela Lombardi(Ospedale San Filippo Neri), Attilio Tordi(ASL Roma)
Cited by 0
Related Papers
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
|Transplantation and Cellular Therapy|2016|106
Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management
|Frontiers in Pharmacology|2023|81
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
|Cancers|2020|78
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice
|Frontiers in Immunology|2020|71
Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation
|Expert Review of Hematology|2016|57